Department of Neurology and Regional Referral Multiple Sclerosis Centre, University-Hospital San Luigi, Orbassano, Italy.
Neurol Sci. 2021 May;42(Suppl 1):25-28. doi: 10.1007/s10072-020-05027-8. Epub 2021 Mar 12.
Pediatric-onset multiple sclerosis (MS) has a highly active and aggressive course, which can have a devastating effect on the physical and cognitive functioning of a child if not treated appropriately with effective disease-modifying drugs. The optimal treatment strategy of pediatric MS is currently unknown and debate continues as to whether treatment escalation or initiation of a highly active therapy provides a better outcome. Here, we present the case of a 16-year-old female diagnosed with highly active relapsing-remitting MS (age at onset: 14 years) who received first-line treatment with fingolimod within 1 year of the first recorded symptom. Since starting fingolimod, the course of the disease has essentially been stable. No new or active lesions were observed in magnetic resonance imaging scans performed at 3 and 12 months after starting fingolimod, and treatment was well tolerated. These data suggest that, in this case, early treatment with first-line fingolimod was able to slow disease progression.
儿童发病多发性硬化症（MS）具有高度活跃和侵袭性的病程，如果不使用有效的疾病修正药物进行适当治疗，可能会对儿童的身体和认知功能造成毁灭性影响。目前，儿童 MS 的最佳治疗策略尚不清楚，关于是否需要升级治疗或开始高活性治疗以获得更好的结果仍存在争议。在这里，我们报告了一例 16 岁女性患者的病例，该患者被诊断为高度活跃的复发缓解型 MS（发病年龄：14 岁），在首次记录症状后 1 年内接受了芬戈莫德的一线治疗。自开始芬戈莫德治疗以来，疾病的进程基本稳定。在开始芬戈莫德治疗后 3 个月和 12 个月进行的磁共振成像扫描中未观察到新的或活动病变，且治疗耐受性良好。这些数据表明，在这种情况下，早期使用一线芬戈莫德治疗能够减缓疾病进展。
